相似文献
1
Recombinant AAV as a platform for translating the therapeutic potential of RNA interference.
Mol Ther. 2014 Apr;22(4):692-701. doi: 10.1038/mt.2013.285. Epub 2013 Dec 19.
2
Design of AAV Vectors for Delivery of RNAi.
Methods Mol Biol. 2019;1950:3-18. doi: 10.1007/978-1-4939-9139-6_1.
3
Design of shRNA and miRNA for Delivery to the CNS.
Methods Mol Biol. 2016;1382:67-80. doi: 10.1007/978-1-4939-3271-9_5.
4
Alleviation of off-target effects from vector-encoded shRNAs via codelivered RNA decoys.
Proc Natl Acad Sci U S A. 2015 Jul 28;112(30):E4007-16. doi: 10.1073/pnas.1510476112. Epub 2015 Jul 13.
5
Effective and Accurate Gene Silencing by a Recombinant AAV-Compatible MicroRNA Scaffold.
Mol Ther. 2020 Feb 5;28(2):422-430. doi: 10.1016/j.ymthe.2019.11.018. Epub 2019 Nov 27.
6
A multiplexed miRNA and transgene expression platform for simultaneous repression and expression of protein coding sequences.
Mol Biosyst. 2016 Jan;12(1):295-312. doi: 10.1039/c5mb00506j.
7
Development of gene therapy for treatment of age-related macular degeneration.
Acta Ophthalmol. 2014 Jul;92 Thesis3:1-38. doi: 10.1111/aos.12452.
8
Inhibition of hepatitis C virus replication using adeno-associated virus vector delivery of an exogenous anti-hepatitis C virus microRNA cluster.
Hepatology. 2010 Dec;52(6):1877-87. doi: 10.1002/hep.23908. Epub 2010 Oct 7.
9
pSM155 and pSM30 vectors for miRNA and shRNA expression.
Methods Mol Biol. 2009;487:205-19. doi: 10.1007/978-1-60327-547-7_10.
10
miRNA and shRNA expression vectors based on mRNA and miRNA processing.
Methods Mol Biol. 2013;936:195-207. doi: 10.1007/978-1-62703-083-0_16.
引用本文的文献
1
Targeting Regulatory Noncoding RNAs in Human Cancer: The State of the Art in Clinical Trials.
Pharmaceutics. 2025 Apr 4;17(4):471. doi: 10.3390/pharmaceutics17040471.
2
Gene therapy breakthroughs in ALS: a beacon of hope for 20% of ALS patients.
Transl Neurodegener. 2025 Apr 16;14(1):19. doi: 10.1186/s40035-025-00477-6.
3
Gene therapy for genetic diseases: challenges and future directions.
MedComm (2020). 2025 Feb 13;6(2):e70091. doi: 10.1002/mco2.70091. eCollection 2025 Feb.
4
Trends on Novel Targets and Nanotechnology-Based Drug Delivery System in the Treatment of Parkinson's disease: Recent Advancement in Drug Development.
Curr Drug Targets. 2024;25(15):987-1011. doi: 10.2174/0113894501312703240826070530.
5
Oligonucleotide Therapies for Facioscapulohumeral Muscular Dystrophy: Current Preclinical Landscape.
Int J Mol Sci. 2024 Aug 21;25(16):9065. doi: 10.3390/ijms25169065.
6
Current developments of gene therapy in human diseases.
MedComm (2020). 2024 Aug 16;5(9):e645. doi: 10.1002/mco2.645. eCollection 2024 Sep.
7
Conditional RNA interference in mammalian cells via RNA transactivation.
Nat Commun. 2024 Aug 10;15(1):6855. doi: 10.1038/s41467-024-50600-w.
8
Adeno-Associated Virus Engineering and Load Strategy for Tropism Modification, Immune Evasion and Enhanced Transgene Expression.
Int J Nanomedicine. 2024 Jul 29;19:7691-7708. doi: 10.2147/IJN.S459905. eCollection 2024.
9
Principle, application and challenges of development siRNA-based therapeutics against bacterial and viral infections: a comprehensive review.
Front Microbiol. 2024 Jun 13;15:1393646. doi: 10.3389/fmicb.2024.1393646. eCollection 2024.
10
Breaking the mold with RNA-a "RNAissance" of life science.
NPJ Genom Med. 2024 Jan 9;9(1):2. doi: 10.1038/s41525-023-00387-4.
本文引用的文献
1
Diversifying microRNA sequence and function.
Nat Rev Mol Cell Biol. 2013 Aug;14(8):475-88. doi: 10.1038/nrm3611. Epub 2013 Jun 26.
2
A largely random AAV integration profile after LPLD gene therapy.
Nat Med. 2013 Jul;19(7):889-91. doi: 10.1038/nm.3230. Epub 2013 Jun 16.
3
Managing microRNAs with vector-encoded decoy-type inhibitors.
Mol Ther. 2013 Aug;21(8):1478-85. doi: 10.1038/mt.2013.113. Epub 2013 Jun 11.
4
Mir-142-3p target sequences reduce transgene-directed immunogenicity following intramuscular adeno-associated virus 1 vector-mediated gene delivery.
J Gene Med. 2013 Jun-Jul;15(6-7):219-32. doi: 10.1002/jgm.2712.
5
Antiviral strategies combining antiretroviral drugs with RNAi-mediated attack on HIV-1 and cellular co-factors.
Antiviral Res. 2013 Apr;98(1):121-9. doi: 10.1016/j.antiviral.2013.02.011. Epub 2013 Feb 21.
6
Dicer-independent processing of short hairpin RNAs.
Nucleic Acids Res. 2013 Apr 1;41(6):3723-33. doi: 10.1093/nar/gkt036. Epub 2013 Feb 1.
7
Preclinical evaluation of an anti-HCV miRNA cluster for treatment of HCV infection.
Mol Ther. 2013 Mar;21(3):588-601. doi: 10.1038/mt.2012.247. Epub 2013 Jan 8.
8
Potent microRNA suppression by RNA Pol II-transcribed 'Tough Decoy' inhibitors.
RNA. 2013 Feb;19(2):280-93. doi: 10.1261/rna.034850.112. Epub 2012 Dec 18.
9
The loop position of shRNAs and pre-miRNAs is critical for the accuracy of dicer processing in vivo.
Cell. 2012 Nov 9;151(4):900-911. doi: 10.1016/j.cell.2012.09.042.
10
Embedding siRNA sequences targeting apolipoprotein B100 in shRNA and miRNA scaffolds results in differential processing and in vivo efficacy.
Mol Ther. 2013 Jan;21(1):217-27. doi: 10.1038/mt.2012.160. Epub 2012 Oct 23.
Zotero 插件